The company ditches lorigerlimab in prostate cancer.
ApexOnco Front Page
Recent articles
But the Day One deal is still 29% below where the shares stood at the start of this year.
Keynote-D18 might have failed on a technicality, but now cash is running out.
ALX2004 starts phase 1, along with the sixth oncology-focused in vivo Car-T.
A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
The speciality pharma will gain the approved Danyelza and a radiopharma pipeline.
A phase 2 trial of the Car-T project BNT211 is withdrawn just months after it began.
